
Avery Hurt
Journalist at Freelance
Science journalist, children's author. NASW, SCBWI. she/her https://t.co/MfJdwOs6nN, @averyhurt.bksy.social
Articles
-
1 week ago |
medcentral.com | Avery Hurt |Barbara Hazelden |Oladimeji Ewumi |Racheal Ede
Increasing numbers of adults are experiencing a progressive syndrome driven by the interaction of chronic kidney disease and cardiovascular disease, obesity, and other metabolic factors, based on data from a new review presented at the National Kidney Foundation Spring Clinical Meeting in Boston. What is Cardiovascular-Kidney-Metabolic Syndrome?
-
3 weeks ago |
medcentral.com | Susan Redline |Angie Drakulich |Avery Hurt |Patrice Wendling
Intensive medical treatment did not reduce the risk of major adverse cardiovascular events (MACE) at 5 years compared with usual care among women with ischemia and nonobstructive coronary artery disease in the WARRIOR trial. Results were presented at the American College of Cardiology (ACC25) annual meeting and are under review by JAMA.
-
3 weeks ago |
medcentral.com | Angie Drakulich |Heidi Splete |Avery Hurt |Patrice Wendling
Once-daily, add-on treatment with the aldosterone synthase inhibitor lorundrostat significantly reduced blood pressure in adults with uncontrolled and treatment-resistant hypertension in a second pivotal trial, ADVANCE-HTN. Results were presented at the American College of Cardiology annual scientific session (ACC.25) this past weekend and are accepted for publication in the New England Journal of Medicine.
-
1 month ago |
medcentral.com | Marc E. Agronin |Marcia Frellick |Avery Hurt |Alexis Pellek
The US FDA has approved the thrombolytic drug tenecteplase (TNKase) for treatment of acute ischemic stroke. The medication was already approved for use in ST-elevation myocardial infarction (STEMI). Yasmin Aziz, MD, assistant professor of clinical neurology and rehabilitation medicine at the University of Cincinnati College of Medicine, spoke with MedCentral to offer some thoughts on how this new approval will affect clinical practice.
-
1 month ago |
medcentral.com | Denise Brodey |Oluoma Aneke |Alexis Pellek |Avery Hurt
About 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine were recalled from the US market by manufacturer Glenmark Pharmaceuticals after tests found potentially harmful impurities above limits imposed by the US Food and Drug Administration (FDA), according to the FDA. Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 2K
- DMs Open
- No

RT @MerriamWebster: During the Renaissance, people in Venice would vote by dropping little balls into an urn. The Italian word for “little…

https://t.co/YoBTRICWK8 UFOs are real. But what about aliens? Scientists are trying to find out. My latest for @SN_Explores

RT @SketchesbyBoze: I'll never forget how book sales surged during the pandemic when businesses closed and everyone was stuck indoors, and…